DLL1 Protein Detection for Sepsis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing severe infections, such as sepsis, are inadequate as they require time-consuming blood cultures that cannot be performed at the point of care, and often yield negative results despite clinical symptoms.
Innovation Solution
An in vitro method using anti-DLL1 capture and labeled detection antibodies to qualitatively and quantitatively detect Delta-like 1 (DLL1) protein in human samples, enabling rapid and reliable diagnosis of severe infections like sepsis as a point-of-care test.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If blood cultures are used to diagnose severe infections, then diagnostic reliability is improved, but diagnostic time is excessive and point-of-care performance is lost
Solution Approach 1:
The invention changes the measured parameter from general bacterial presence (blood culture) to specific host response biomarker DLL1 levels, enabling rapid detection within minutes while maintaining diagnostic reliability for severe infections
Solution Approach 2:
The invention replaces the complex mechanical blood culture system with a simplified immunological detection system using antibodies and biomarker measurement, eliminating the need for prolonged incubation while preserving diagnostic accuracy
2Reliability
If blood cultures are used to diagnose severe infections, then diagnostic accuracy is improved, but ease of operation at point of care deteriorates
Solution Approach 1:
The invention extracts the essential diagnostic information (DLL1 biomarker levels) from the complex blood culture process, creating a standalone rapid test that can be performed at point of care without requiring laboratory infrastructure
Solution Approach 2:
The invention introduces DLL1 as an intermediary biomarker that reflects the host response to infection, allowing indirect but rapid assessment of severe infection status without direct bacterial culture
3Measurement precision
If conventional diagnostic methods are used, then detection of low biomarker levels is insufficient, but measurement precision for DLL1 must be high
Solution Approach 1:
The invention changes the detection parameter to target DLL1 protein levels specifically, using antibody-based detection methods that provide high sensitivity for low concentration biomarkers while maintaining rapid test performance
Solution Approach 2:
The invention employs signal amplification mechanisms (analogous to vibration amplification) through labeled antibodies and detection systems that enhance the measurable signal from low-level DLL1 protein, achieving high measurement precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively detects DLL1 protein at low levels in human samples, providing a rapid and reliable diagnostic tool for severe infections, particularly sepsis, that can be performed at the time and place of patient care.
Implementation Method 1
an anti-DLL1 capture antibody and/or a labeled anti-DLL1 detection antibody
Data Source
AI summary
The invention relates to in vitro methods for detecting Delta-like 1 (DLL1) protein using an anti-DLL 1 capture antibody and a labeled anti-DLL1 detection antibody. According to the invention, these antibodies can be used in an in vitro method to diagnose a severe infection, in particular a sepsis.